Clinical Trials Directory

Trials / Terminated

TerminatedNCT00023946

BMS-247550 in Treating Patients With Liver or Gallbladder Cancer

A Phase II Trial Of The Epothilone B Analog BMS-247550 (NSC 710428D) In Patients With Hepatobiliary Cancer

Status
Terminated
Phase
Phase 2
Study type
Interventional
Enrollment
50 (actual)
Sponsor
National Cancer Institute (NCI) · NIH
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

Phase II trial to study the effectiveness of BMS-247550 in treating patients who have liver or gallbladder cancer. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.

Detailed description

PRIMARY OBJECTIVES: I. Determine the objective response rate of patients with hepatobiliary cancer treated with BMS-247550. II. Determine the toxicity of this drug in these patients. III. Determine the duration of response, median and overall survival, and time to progression in patients treated with this drug. OUTLINE: This is a multicenter study. Patients receive BMS-247550 IV over 3 hours on day 1. Treatment repeats every 21 days for at least 2 courses in the absence of disease progression or unacceptable toxicity. Patients are followed every 6 weeks until disease progression

Conditions

Interventions

TypeNameDescription
DRUGixabepiloneGiven IV
OTHERlaboratory biomarker analysisCorrelative studies

Timeline

Start date
2001-08-01
Primary completion
2005-07-01
Completion
2009-11-01
First posted
2003-01-27
Last updated
2014-05-14

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT00023946. Inclusion in this directory is not an endorsement.